Novanta（NOVT）株式概要
ノバンタ社は、その子会社とともに、精密医療、精密製造、医療ソリューション、ロボット工学および自動化ソリューション、高度外科手術ソリューションを米国内外で提供している。 詳細
NOVT Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Novanta Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$127.87 |
| 52週高値 | US$149.95 |
| 52週安値 | US$98.27 |
| ベータ | 1.65 |
| 1ヶ月の変化 | 9.25% |
| 3ヶ月変化 | -4.80% |
| 1年変化 | 4.83% |
| 3年間の変化 | -21.26% |
| 5年間の変化 | -0.79% |
| IPOからの変化 | 702.31% |
最新ニュース
NOVT: Future Earnings Power Will Rely On Executing Stronger Margins
Narrative update on Novanta The consensus analyst price target for Novanta has been raised by $12 to $150. Analysts cite updated models after Q4 results that indicate potential for stronger sales and margin performance.NOVT: Future Earnings Power Will Rely On Accelerating Sales And Margins
Analysts have trimmed their fair value estimate for Novanta from $160 to $157, reflecting a slightly higher discount rate and a modestly lower future P/E assumption, while still pointing to expectations for improving sales and margins after recent model updates. Analyst Commentary Bullish Takeaways Bullish analysts see room for the shares to move toward their updated fair value range, supported by model revisions that assume improving sales trends and margin recovery after recent results.NOVT: Future Earnings Power Will Rely On Accelerating Margins
Analysts have lifted their price target on Novanta to $150 from $138, citing updated Q4 models that suggest the company may be positioned for faster sales growth and margin expansion. Analyst Commentary Bullish Takeaways Bullish analysts point to the raised price target to $150 as a sign that updated Q4 assumptions support a higher valuation range for the shares.Recent updates
NOVT: Future Earnings Power Will Rely On Executing Stronger Margins
Narrative update on Novanta The consensus analyst price target for Novanta has been raised by $12 to $150. Analysts cite updated models after Q4 results that indicate potential for stronger sales and margin performance.NOVT: Future Earnings Power Will Rely On Accelerating Sales And Margins
Analysts have trimmed their fair value estimate for Novanta from $160 to $157, reflecting a slightly higher discount rate and a modestly lower future P/E assumption, while still pointing to expectations for improving sales and margins after recent model updates. Analyst Commentary Bullish Takeaways Bullish analysts see room for the shares to move toward their updated fair value range, supported by model revisions that assume improving sales trends and margin recovery after recent results.NOVT: Future Earnings Power Will Rely On Accelerating Margins
Analysts have lifted their price target on Novanta to $150 from $138, citing updated Q4 models that suggest the company may be positioned for faster sales growth and margin expansion. Analyst Commentary Bullish Takeaways Bullish analysts point to the raised price target to $150 as a sign that updated Q4 assumptions support a higher valuation range for the shares.NOVT: Future Earnings Power Will Rely On Accelerating Margins
Analysts have lifted their fair value estimate for Novanta to $160 from $154, supported by updated models that reflect expectations for accelerating sales and margins following recent Q4 results and a higher Street price target of $150 from $138. Analyst Commentary Recent commentary points to a more constructive view on Novanta following its Q4 results, with updated models feeding into a higher fair value framework and a Street price target of $150.NOVT: Stable Outlook Will Rely On Steady Margins And Earnings Multiple
Narrative Update: Novanta Analyst Price Target The analyst price target for Novanta is unchanged at $154, as analysts keep their assumptions for fair value, discount rate, revenue growth, profit margin and future P/E essentially steady. Valuation Changes Fair Value: $154.00 remains effectively unchanged compared with the prior estimate of $154.NOVT: Equity Units Offering Will Support Balance Sheet And Future Deals
Analysts have nudged their price target on Novanta slightly higher to reflect modest tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions, framing the move as fine tuning rather than a major reset in expectations. What's in the News Novanta plans to look for acquisitions and investments, signaling an interest in adding to its portfolio of businesses (Key Developments).NOVT: Equity Units And Share Repurchases Will Support Balance Sheet And Future Deals
Analysts now keep their price target for Novanta effectively unchanged at about $154.00. They point to steady assumptions around discount rate, revenue growth, profit margin and future P/E as the key drivers of their view.NOVT: Equity Units Offering Will Strengthen Balance Sheet And Support Future Deals
Analysts have maintained their fair value estimate for Novanta at approximately $154. They cite only marginal adjustments to the discount rate, long term revenue growth, profit margin assumptions, and future P/E, which do not materially change their overall outlook.NOVT: New Equity Raise Will Strengthen Balance Sheet And Support Future Deals
Analysts have maintained their price target for Novanta at approximately $154 per share. This reflects a steady outlook, as incremental adjustments to discount rate assumptions and long term growth and profitability estimates are viewed as too minor to warrant a change in fair value.NOVT: Expanded Equity Offering And Buybacks Will Drive Long Term Shareholder Value
Analysts have nudged their price target for Novanta slightly higher to align with its updated fair value of $154.00, reflecting modestly stronger confidence in the company’s steady growth and margin profile. What's in the News Novanta completed a $550 million composite tangible equity units offering, issuing 11 million units priced at $50 each, with a $1.375 discount per unit (Key Developments).NOVT: Expanded Buyback Authorization Will Increase Shareholder Value Going Forward
Narrative Update on Novanta: Analyst Price Target Change Analysts have maintained Novanta's fair value estimate at $154. They cited improved profitability metrics, which offset slight adjustments in the discount rate and growth projections.NOVT: Equity Buyback Expansion And Profit Margin Gains Will Drive Upside
Analysts have raised their fair value estimate for Novanta from $141.50 to $154.00 per share, citing expectations for stronger future revenue growth and improved profit margins, even though the discount rate is slightly higher. What's in the News Novanta Inc.Novanta Inc. (NASDAQ:NOVT) Looks Just Right With A 30% Price Jump
Oct 28
Is Now The Time To Look At Buying Novanta Inc. (NASDAQ:NOVT)?
Oct 07Novanta: The Solution To Elevated Expectations Is Lower Prices
Sep 29Novanta's (NASDAQ:NOVT) Returns Have Hit A Wall
Sep 13Robotics And Healthcare Demand Will Expand Market Opportunities
Novanta’s fair value outlook remains unchanged, as both the discount rate and future P/E shifted only marginally, leaving the consensus analyst price target steady at $141.50. What's in the News Novanta projects third quarter 2025 GAAP revenue of $244 million to $247 million and full year 2025 GAAP revenue of $970 million to $985 million.Novanta Inc.'s (NASDAQ:NOVT) Share Price Matching Investor Opinion
Aug 29Are Novanta Inc. (NASDAQ:NOVT) Investors Paying Above The Intrinsic Value?
Jun 16Returns At Novanta (NASDAQ:NOVT) Appear To Be Weighed Down
May 20Here's Why Novanta (NASDAQ:NOVT) Can Manage Its Debt Responsibly
May 03Should You Think About Buying Novanta Inc. (NASDAQ:NOVT) Now?
Apr 19Novanta: A Trusted Yet Premium Technology Partner
Apr 06Novanta Inc.'s (NASDAQ:NOVT) Stock Retreats 27% But Earnings Haven't Escaped The Attention Of Investors
Apr 05There May Be Some Bright Spots In Novanta's (NASDAQ:NOVT) Earnings
Mar 05Novanta (NASDAQ:NOVT) Has Some Way To Go To Become A Multi-Bagger
Feb 09Is Novanta (NASDAQ:NOVT) A Risky Investment?
Jan 24Should You Investigate Novanta Inc. (NASDAQ:NOVT) At US$151?
Jan 07Novanta: Delayed Recovery And Prolonged Struggles Ahead, Downgrade To Sell
Jan 01Novanta Inc.'s (NASDAQ:NOVT) Business Is Yet to Catch Up With Its Share Price
Dec 21Novanta (NASDAQ:NOVT) May Have Issues Allocating Its Capital
Oct 15What You Can Learn From Novanta Inc.'s (NASDAQ:NOVT) P/S
Sep 12Novanta Inc.: Overpriced In A Weak Demand Market. Here's Why It's A Hold
Sep 02
Innovative Medical Devices And Tactical Acquisitions Poised To Accelerate Company Growth
Focusing on medical devices with new products might significantly boost future revenue through innovation, aiming for notable revenue from new launches by 2025.Is It Too Late To Consider Buying Novanta Inc. (NASDAQ:NOVT)?
Aug 24Novanta Inc.'s (NASDAQ:NOVT) Intrinsic Value Is Potentially 21% Below Its Share Price
Aug 02Novanta (NASDAQ:NOVT) Might Be Having Difficulty Using Its Capital Effectively
Jun 22Does Novanta (NASDAQ:NOVT) Have A Healthy Balance Sheet?
May 30Investors Still Waiting For A Pull Back In Novanta Inc. (NASDAQ:NOVT)
May 08株主還元
| NOVT | US Electronic | US 市場 | |
|---|---|---|---|
| 7D | -4.6% | -2.8% | 0.8% |
| 1Y | 4.8% | 97.8% | 27.8% |
業界別リターン: NOVT過去 1 年間で97.8 % の収益を上げたUS Electronic業界を下回りました。
リターン対市場: NOVTは、過去 1 年間で27.8 % のリターンを上げたUS市場を下回りました。
価格変動
| NOVT volatility | |
|---|---|
| NOVT Average Weekly Movement | 6.3% |
| Electronic Industry Average Movement | 9.1% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: NOVT 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: NOVTの 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1968 | 3,000 | Matthijs Glastra | www.novanta.com |
ノバンタ・インク（Novanta Inc.）は、その子会社とともに、精密医療、精密製造、医療ソリューション、ロボット工学およびオートメーション・ソリューション、先進手術ソリューションを米国内外で提供している。同社はオートメーション・イネーブリング・テクノロジーズ部門とメディカル・ソリューション部門を運営している。精密医療・製造部門では、レーザービームのステアリング・スキャニング・ソリューション、レーザー光源、ロボット・精密モーション、ロボット・エンド・オブ・アーム・ツーリング、ベアリング・スピンドルの設計・製造・販売を行っている。このセグメントでは、高度な産業プロセス、高度な産業用および医療用ロボット、その他の医療およびライフサイエンス自動化アプリケーション、眼科アプリケーションなどの医療用レーザー処置に対応している。メディカル・ソリューションズ部門は、医療用気腹器、ポンプ、関連ディスポーザブル、画像処理、識別、RFIDソリューション、高度モーションコントロールソリューション、ライトエンジン、統合手術室技術など、幅広い医療グレードの技術を提供している。同社は以前はGSI Group, Inc.として知られていたが、2016年5月に社名をNovanta Inc.に変更した。ノバンタ・インクは1968年に法人化され、マサチューセッツ州ベッドフォードに本社を置いている。
Novanta Inc. 基礎のまとめ
| NOVT 基礎統計学 | |
|---|---|
| 時価総額 | US$4.55b |
| 収益（TTM） | US$53.83m |
| 売上高(TTM) | US$980.60m |
84.6x
PER（株価収益率4.6x
P/SレシオNOVT は割高か？
公正価値と評価分析を参照収益と収入
| NOVT 損益計算書（TTM） | |
|---|---|
| 収益 | US$980.60m |
| 売上原価 | US$545.32m |
| 売上総利益 | US$435.28m |
| その他の費用 | US$381.46m |
| 収益 | US$53.83m |
直近の収益報告
Dec 31, 2025
次回決算日
May 11, 2026
| 一株当たり利益（EPS） | 1.51 |
| グロス・マージン | 44.39% |
| 純利益率 | 5.49% |
| 有利子負債／自己資本比率 | 19.1% |
NOVT の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/03 08:56 |
| 終値 | 2026/05/01 00:00 |
| 収益 | 2025/12/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Novanta Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8
| アナリスト | 機関 |
|---|---|
| Robert Mason | Baird |
| Quinn Fredrickson | Baird |
| Andrew Buscaglia | Berenberg |